

Application of Dexemedetomidine as Monitored Anesthesia Care for Surgical Procedural Sedation

Ali M. Saad^{1*} and Aamil Haameem²

¹Department of Anesthesia and Critical Care, Ahmadi hospital, Ahmadi-Kuwait

²Department of Anesthesia and Critical Care, Ahmadi hospital, Ahmadi-Kuwait

*Corresponding author

Dr. Ali Saad, Specialist of Anesthesia, critical care- MBBS, MS anesthesia, critical care-Mansoura University, faculty of medicine, Mansoura-Egypt, Tel.: +96565520979; Fax: +96523875008; E-mail: profanesthesia@yahoo.com

Submitted: 16 May 2018; Accepted: 28 May 2018; Published: 01 June 2018

Abstract

Background: Anesthesia for short procedures or ambulatory surgery as (awake fiber-optic bronchoscopy, ophthalmic procedures, back injections, awake craniotomy and other minor procedures) has several challenges to an anesthetist. Use of Dexemedetomidine (Precedex) medication for procedural sedation in non-intubated patients could be used prior to or during surgical procedures. Dexemedetomidine has some characters of ideal anesthetic for perioperative use as rapid start of action and termination with low lipid solubility, easy to give by infusion, achieve a well balanced sedation, can maintain airway reflexes, and less effect on respiration.

Methodology: 41 patients of either sex, aged 18 to 60 yrs of ASA grade I and II were used as a sample; all adults over 18 years (most surgical patients coming at that time). All pediatrics, patients with multiple co morbidities, patient's refusing; known or admitted alcohol or drug abusers, allergic to the drugs involved in the study and prisoners were excluded. Patients were randomized to receive a Loading dose of 0.5 to 1 mcg/kg IV over 10 minutes then maintenance IV infusion in dosage regimen of 0.2 to 0.4 mcg/kg/hour IV, titrate to effect.

Results: 41 cases observed for vital signs, depth of sedation, patient response, and arousal effect. Results showed 30 cases got good smooth deep sedation without complications. 11 cases got low blood pressures with low heart rates needed stopping infusion, pressor support medications.

Conclusion: Precedex dosing should be individualized and titrated to desired clinical response. It should be administered using a controlled infusion device with full monitoring devices and oxygen supplement.

Keywords

- **Dexemedetomidine (DEX):** Precedex[®]; Hospira, Lake Forest, IL, USA; and Dexdor; Orion Corporation, Espoo, Finland.
- Procedural Sedation
- Operation Theatre
- Surgical Procedures
- Controlled Infusion
- Clonidine
- α - alpha receptors - α 2-agonist
- Awake Intubation
- Fiber-optic Intubation

Data Availability

The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and their supporting information files.

Introduction

Anesthesia for short procedures or ambulatory surgery as (awake fiber-optic bronchoscopy, ophthalmic procedures, back injections,

awake craniotomy and other minor procedures) has several challenges to an anesthetist. The patient must be sedated to a state where patient can tolerate the surgical procedure, alert responding and co-operative like in awake craniotomy for neurocognitive testing [1].

Adequate anesthesia and analgesia have to be achieved to level that patient is alert, comfortable, responding without pain. The depth of sedation, anxiolysis should be titrated to avoid adverse events as obtunded airway, affection of respiration, high carbon dioxide, coughing, low blood pressure and other hemodynamic abnormalities [2, 3].

Dexemedetomidine has some characters of ideal anesthetic for perioperative use as rapid start of action and termination with low lipid solubility, easy to give by infusion, achieve a well balanced sedation, can maintain airway reflexes, and less effect on respiration [4].


Now, it has been found that Dexemedetomidine without any known active or toxic metabolites therefore; it is USA Food and Drug

Administration (FDA) approved for sedation via IV bolus and continuous administration up to 24 h on intubated patients and for procedural anxiolysis in locations outside the critical care unit (ICU) and operation theatre [5].

Structure-Organic Chemistry

Precedex (Dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection is a clear solution tolerable for intravenous injection after dilution. Dexmedetomidine HCL is the S-isomer of medetomidine and is chemically characterized as (+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole monohydrochloride [6].


Precedex has an empirical formula is $C_{13}H_{16}N_2 \cdot HCl$ - Figure 1



Dexmedetomidine hydrochloride is a white or almost white powder that is freely soluble in water and has a PKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89.


Precedex Injection is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of Dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of Dexmedetomidine and 9 mg of sodium chloride in water and is to be used after dilution. The solution is preservative-free and contains no additives or chemical stabilizers [7, 8].

It is related chemically to clonidine, but it is more attar-actability for α_2 over α_1 -receptors (with ratio of 1,600:1, compared to 200:1 for clonidine) - (Figure: 2) [9].



Mechanism of Action (Figure 3)

Dexmedetomidine is a selective α_2 -adrenergic receptor drug agonist. It is active at a variety of sites throughout the central neuronal system. The sedative and anxiolytic effects of Dexmedetomidine result primarily from its action on the locus ceruleus of the brainstem. Stimulation of α_2 -adrenergic receptors at this location inhibits central sympathetic output, leading to more firing of inhibitory neurons. The action of Dexmedetomidine at α_2 -adrenergic receptors in the dorsal horn of the spinal cord modifies release of substance P and produces its painless effects [9, 10].



Pharmacokinetics

With intravenous (IV) injection, Dexmedetomidine has a rapid distribution, with a 50% distribution time of approximately 6 minutes in adults [11, 12]. It is extensively distributed, with a volume of distribution of 118 L and protein binding of 94%. Dexmedetomidine exhibits linear kinetics over the recommended dosage range of 0.2 to 0.7mcg/kg/hr. It is extensively metabolized through both the cytochrome P450 enzyme system, by aliphatic hydroxylation via CYP2A6, and direct glucuronidation. N-glucuronidation produces inactive metabolites, while aliphatic hydroxylation produces active 3-hydroxy-dexmedetomidine, which then undergoes glucuronidation, and 3-carboxy-dexmedetomidine. N-methylation produces active 3-hydroxy-N-methyl-dexmedetomidine, 3-carboxy-N-methyl-dexmedetomidine, and Dexmedetomidine-N-methyl-O-glucuronide. These metabolites are excreted in urine (95%) and feces (4%). Dexmedetomidine has a terminal elimination half-life of approximately 2 hours and a clearance of 39 L/hr in adults. Dose reduction is needed for patients with hepatic impairment [12].

Indications

Dexmedetomidine can be used for anxiolysis, relief of pain and stress intraoperative for many as following: [13, 14, 15, 16].

- Airway procedures as Rigid bronchoscopy, awake fiber-optic bronchoscopy .
- Difficult intubation algorithm.
- Anesthetic adjuvant in Bariatric surgery and sleep apnea patients.
- Arthroscopic knee surgery.
- Neurosurgical procedures as awake craniotomy.
- Posterior spine fusions; DEX Lowers requirements for propofol and inhalation agents
- Cardiac surgery induction
- Painful procedures as Extracorporeal shock-wave lithotripsy
- Burn dressing change
- Lumbar puncture
- Bone marrow biopsy
- Central venous line placement
- Chest tube insertion
- Dental procedures
- Monitored Anesthesia Care as gynecological, urological, burns patients, trauma patients, ophthalmic procedures, back injections, awake craniotomy, drug-induced sleep endoscopy, magnetic resonance imaging (MRI) and Anterior mediastinal mass biopsy [15, 16].

Methodology

The study was approved by the appropriate Institutional Review Board (IRB), and written informed consent was obtained from all adult subjects participating in the study.

The study done by authors; Drs. Ali Saad, Aamil Haameem (registration not applicable)

41 patients of either sex, aged 18 to 60yrs of ASA grade I and II were used as a sample; all adults over 18 years (most surgical patients coming at that time).

All pediatrics, patients with multiple comorbidities, Patient's refusing; known or admitted alcohol or drug abusers, allergic to the drugs involved in the study and prisoners were excluded.

41 Patients were randomized to receive a Loading dose of 0.5 to 1 mcg/kg IV over 10 minutes then maintenance IV infusion in dosage regimen of 0.2 to 0.4 mcg/kg/hour IV, titrate to effect.

Start loading dosage of 0.5-1 mcg/kg IV over 10 minutes then Maintenance 0.2-0.4 mcg/kg/hour IV titrate to effect.

35 patients did not need any midazolam adjuvant as sedative during procedure. Other 6 patients needed only 2mg IV boluses.

Results

Our Research study is a prospective, clinical case study

Study was done on adults (target population) with total 41 cases in number. All patients were ASA I, II without multiple co-morbidities.

Dexmedetomidine injection is available in 200 mcg/2ml clear glass vials (100mcg/ml); for single use only.

11 patients of total 41 cases in the study had marked bradycardia with slow heart rate reached 30 to 40 beats per min and lower blood pressure (systolic blood pressure dropped to 80 to 90 mmHg) on monitor. Other 30 cases got good smooth deep sedation without complications.

It was found that giving rapid bolus over short time can cause rapid affection on heart rate and blood pressure; that's why tapered IV infusion was preferred mode of Dexmedetomidine administration with good monitoring of vital signs and giving IV fluids with standby pressor agents beside patient.

Most of patients responded well to IV fluids, pressor agents as ephedrine or phenylephrine with oxygen therapy during procedure.

Discussion

Precedex administration for sedation of non-intubated patients prior to and/or during surgical and other procedures under monitored anesthesia care was evaluated in randomized clinical trial including safety and efficacy. Precedex in patients undergoing awake fiberoptic intubation prior to a surgical or diagnostic procedure also was included in the study.

Dexmedetomidine may be used as a total intravenous anesthetic agent in certain patients if doses are increased to a high tolerable level [15, 16].

Previous studies on assessing Dexmedetomidine as a general anesthetic found that supplementary agents were necessary, but the doses of Dexmedetomidine had not reached the high levels of administration reported here [16].

Dosage Regimens


Initiation of Procedural Sedation

- For adults: a loading infusion of one mcg/kg over 10 **minutes**. For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 **minutes**.
- **For awake fiber optic intubation in adult patients:** a loading infusion of one mcg/kg over 10 **minutes**.
- **For patients over 65 years of age:** a loading infusion of 0.5 mcg/kg over 10 minutes.
- **For adult patients with impaired hepatic function:** a dose reduction should be done [17].

Maintenance of Procedural Sedation

- For adult patients: Maintenance infusion is started at 0.6 mcg/kg/hour and titrated according to best level of sedation, dose adjustment needed in renal patients.
- For intubation: a maintenance infusion of 0.7 mcg/kg/hour is preferred till the endotracheal tube is secured.
- For patients over 65 years of age: doses range from 0.2 to 1 mcg/kg/hour. [17, 18].

Clinical Effects: Shown in Figure: 4



Cardiovascular

Dexmedetomidine has a biphasic blood pressure effect in form of a short high blood pressure phase with following lower. The two staged effect is mediated by two different α_2 -receptors subtypes' receptors: α_2 -B receptors which mediates initial high blood pressure stage and later lower blood pressure is mediated by the α_2 -A-receptors. In young age with high levels of parasympathetic tone; low heart rate and sometimes cardiac arrest have been reported but they were well treated with anti-parasympathetic agents as atropine, glycopyrrolate [19].

Centrally

Dexmedetomidine lowers cerebral blood flow and cerebral metabolic oxygen consumption with limited effect on intracranial pressure (ICP). Dexmedetomidine modulates cognitive performance with sedative, analgesic, and anxiolytic effects. Studies found that DEX has some neuroprotective effects through lowering circulating and brain catecholamines levels [20, 21].

Respiratory

Dexmedetomidine can affect respiration as deep sleep state does without depression. It doesn't affect respiration rate or ventilation in spontaneously breathing critical care patients postoperative. It can facilitate weaning and removal of endotracheal tube (recovery) in trauma/ surgical critical care unit patients with stable hemodynamics and preserved respiration [22, 23, 24].

Others

Dexmedetomidine enhances peripheral pre-synaptic α_2 -adrenergic receptors which inhibit the firing catecholamines leading to diminished sympathetic response to surgery. Some studies concluded that Dexmedetomidine can cause more excretion of water and salt in urine (more urine output). It was found that Dexmedetomidine doesn't inhibit production of steroids if used as intravenous infusion for short time; although it is imidazole form (unlike etomidate) [25, 26].

Adverse effects

Dexmedetomidine may cause unwanted systemic effects as low or high blood pressure, slow heart rate, dry oral cavity, sense of vomiting or gastric discomfort, high temperature, rigors, cyanosis and weak muscles. It was also reported that Dexmedetomidine can cause cardiac abnormalities, heart block or even cardiac arrest, inverted T-wave, rapid heart rate, myocardial ischemia, syncopal attacks and rare heart failure. It may cause airway obstruction, inadequate respiration, tingling nerve sensation or slight paralysis and high blood levels of potassium, glucose or lactic acid [26-28].

Conclusion

Dexmedetomidine is a very useful medication enlisted in the family of drugs used in anesthesia. It can be utilized in a wide range of applications as discussed before at the same time requiring caution during its use. High cost is its limiting factor.

Decreases in heart rate and blood pressure were modest, predictable and well treated. Some patients were arousable, responding to calls. DEX produced good sedation with anxiolysis and lowered need for other sedatives.

Dexmedetomidine should be used with caution in patients with low circulatory volume, shock or accompanied with hypnotics and analgesics.

Dexmedetomidine dosage should be individualized and titrated to desired clinical response.

Dexmedetomidine is not indicated for infusions longer than 24 hours. Precedex should be administered using a controlled infusion device.

Arterial Blood pressure, Heart rate, Respiratory rate and Oxygen saturation levels should be monitored during and after the infusion as clinically applicable.

Besides, patients should be instructed to report symptoms occurring within 48 hours after Dexmedetomidine injection as weakness, disorientation, more sweating, weight loss, abdominal pain, diarrhea, constipation, affected level of consciousness.

Dexmedetomidine has become a part of ambulatory anesthesia, offers anesthetic sparing and maintains hemodynamics.

As pharmacological effects of Dexmedetomidine can be reversed by α_2 -AR antagonist atipamezole, addition of Dexmedetomidine with atipamezole can provide titratable form of sedation in the future.

Conflict of Interests

The authors declare no competing financial interests.

References

1. Piccioni F, Fanzio M (2008) Management of anesthesia in awake craniotomy. *Minerva Anesthesiol* 74: 393-408.
2. Basavaraj G Kallapur, Raghavendra Bhosale (2012) Use of Dexmedetomidine infusion in anaesthesia for awake craniotomy. *Indian J Anaesth* 56: 413-415.
3. Mack PF, Perrine K, Kobylarz E, Schwartz TH, Lien CA (2004) Dexmedetomidine and neurocognitive testing in awake craniotomy. *J Neurosurg Anaesthesiol* 16: 20-5.
4. M. Mahmoud, K. P. Mason (2015) Dexmedetomidine: review, update, and future considerations of paediatric perioperative and procedural applications and limitations. *British Journal of Anaesthesia* 115:171-182.
5. Sanders RD, Sun P, Patel S, Li M, Maze M, et al. (2010) Dexmedetomidine provides cortical neuroprotection: impact on anesthetic-induced neuroapoptosis in the rat developing brain. *Acta Anaesthesiol Scand* 54: 710-769.
6. Hospira Inc. Lake Forest, IL 60045 USA. Revised: May 2016.
7. Precedex™ Product Monograph - PRECEDEX™ (2017) Dexmedetomidine Hydrochloride for Injection. Hospira Healthcare Corporation.
8. Aantaa R, Kallio A, Virtanen R (1993) Dexmedetomidine, a novel α_2 -adrenergic agonist. A review of its pharmacodynamic characteristics. *Drugs of the Future* 18: 49-56.
9. Barry C. Boyd, Steven J.Sutter (2011) Dexmedetomidine Sedation for Awake Fiber optic Intubation of Patients with Difficult Airways Due To Severe Odontogenic Cervicofacial Infections. *Journal of Oral and Maxillofacial Surgery* 69: 1608-1612.
10. R.K, Miller R (2000) Preoperative Medication in Basis of Anesthesia; 4th Edition- Stoelting: p 119-130.
11. Hobbs WR, Rall TW, Verdoorn TA (1996) Hypnotics and Sedatives; Ethanol In, Goodman and Gillman's The Pharmacological Basis of Therapeutics 364-367.
12. M Aho, Erkola (1992) Dexmedetomidine Infusion for Maintenance of Anesthesia in Patients Undergoing Abdominal Hysterectomy. *Anesth Analg* 75: 940-946.
13. S Paul, DP Bhattacharjee, S Ghosh, S Dawn, N Chatterjee (2010) Efficacy of intraarticular Dexmedetomidine for postoperative analgesia in arthroscopic knee surgery. *Ceylon Med J* 55: 111-115.
14. Shagufta Naaz, Erum Ozair (2014) Dexmedetomidine in Current Anesthesia Practice- A Review. *J Clin Diagn Res* 8: GE01-GE04.
15. SD Bergese, B Khabiri, WD Roberts, MB Howie, TD Mc Sweeney, et al. (2007) Dexmedetomidine for conscious sedation in difficult awake fiber-optic intubation cases. *J Clin Anesth* 19: 141-144.
16. Michael A E Ramsay, David L Luteran (2004) Dexmedetomidine as a Total Intravenous Anesthetic Agent. *Anesthesiology* 101: 787-790.
17. Candiotti KA1, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, et al. (2010) Monitored Anesthesia Care with Dexmedetomidine: A Prospective, Randomized, Double-

-
- Blind, Multicenter Trial. *Ambulatory Anesthesia* 110: 47-56.
18. Manpreet Kaur, P M Singh (2011) Current role of Dexemedetomidine in clinical anesthesia and intensive care. *Anesthesia: Essays and Researches* 5: 128-133.
 19. Philipp M, Brede M, Hein L (2002) Physiological significance of alpha (2)-adrenergic receptor subtype diversity: One receptor is not enough. *Am J Physiol Regul Integr Comp Physiol* 283: 287-295.
 20. Franowicz JS, Arnsten AF (1998) The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. *Psychopharmacology (Berl)* 136: 8-14.
 21. Bekker A, Sturaitis MK (2005) Dexemedetomidine for neurological surgery. *Neurosurgery* 57: 1-10.
 22. Venn RM, Hell J, Grounds RM (2000) Respiratory effects of Dexemedetomidine in the surgical patient requiring intensive care. *Crit Care* 4: 302-308.
 23. Hsu YW, Cortinez LI, Robertson KM, Keifer JC, Sum-Ping ST, et al. (2004) Dexemedetomidine pharmacodynamics: Part I: Cross-over comparison of the respiratory effects of Dexemedetomidine and remifentanyl in healthy volunteers. *Anesthesiology* 101: 1066-1076.
 24. Siobal MS, Kallet RH, Kivett VA, Tang JF (2006) Use of Dexemedetomidine to facilitate extubation in surgical intensive-care-unit patients who failed previous weaning attempts following prolonged mechanical ventilation: A pilot study. *Respir Care* 51: 492-496.
 25. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colincio MD (2000) The effects of increasing plasma concentrations of Dexemedetomidine in humans. *Anesthesiology* 93: 382-394.
 26. Venn R, Bryant A, Hall GM, Grounds RM (2001) Effects of Dexemedetomidine on adrenocortical function and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. *Br J Anaesth* 86: 650-656.
 27. Morgan GE, Mikhail MS, Murray MJ (2006) In: *Preoperative Medication in Clinical Anaesthesia*. 4th ed. Morgan GE, Mikhail MS, Murray MJ, editors. New York: Mc graw Hill 248.
 28. Akeju O, Pavone KJ, Westover MB (2014) A comparison of propofol and Dexemedetomidine-induced electroencephalogram dynamics using spectral and coherence analysis. *Anesthesiology* 121: 978-898.

Copyright: ©2018 Ali Saad. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.